1. Fig. 2. Increased CD19 CAR-T cell expansion and persistence after Cy/Flu lymphodepletion.
Increased CD19 CAR-T cell expansion and persistence after Cy/Flu lymphodepletion. (A and B) Peak CD4+/EGFRt+ (A) and CD8+/EGFRt+ (B) CAR-T cell numbers after the first CAR-T cell infusion in relation to the percentage of CD19+ cells (normal and malignant CD19+ B cells) in the bone marrow before lymphodepletion chemotherapy for each patient. (C) CAR-T cell persistence in the blood as integrated transgene copies per microgram of DNA in two patients who received a cycle of Cy or Cy/E lymphodepletion chemotherapy and CAR-T cell infusion followed by a second cycle of Cy lymphodepletion chemotherapy and CAR-T cell infusion. Integrated transgene copies were determined by quantitative real-time fluorescence polymerase chain reaction (QPCR) for distinct sequences located in the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) or Flap/EF1α regions of the lentivirus. (D and E) Mean ± SEM of CD4+/EGFRt+ (D) and CD8+/EGFRt+ (E) CAR-T cell counts in the blood on the indicated days after CAR-T cell infusion for patients treated with 2 × 107 EGFRt+ cells/kg after either Cy or Cy/E lymphodepletion (No Flu) or Cy/Flu lymphodepletion (Cy/Flu). (F) CAR-T cell persistence in blood of patients who received Cy or Cy/E lymphodepletion (No Flu, black; n = 9) compared to Cy/Flu lymphodepletion (red; n = 18) is shown as FlapEF1α integrated transgene copies per microgram of DNA. CAR-T cell persistence data are truncated at the time of HCT for patients who underwent autologous or allogeneic HCT after CAR-T cell infusion.
Cameron J. Turtle et al., Sci Transl Med 2016;8:355ra116
Published by AAAS